Biomimetic nanobubbles for triple-negative breast cancer targeted ultrasound molecular imaging

Natacha Jugniot; Tarik F Massoud; Jeremy J Dahl; Ramasamy Paulmurugan

doi:10.1186/s12951-022-01484-9

Biomimetic nanobubbles for triple-negative breast cancer targeted ultrasound molecular imaging

J Nanobiotechnology. 2022 Jun 10;20(1):267. doi: 10.1186/s12951-022-01484-9.

Authors

Natacha Jugniot^{1

2}, Tarik F Massoud¹, Jeremy J Dahl², Ramasamy Paulmurugan^{3

4

5}

Affiliations

¹ Molecular Imaging Program at Stanford (MIPS), and Bio-X Program, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94305-5427, USA.
² Canary Center at Stanford for Cancer Early Detection, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94305-5427, USA.
³ Molecular Imaging Program at Stanford (MIPS), and Bio-X Program, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94305-5427, USA. paulmur8@stanford.edu.
⁴ Canary Center at Stanford for Cancer Early Detection, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94305-5427, USA. paulmur8@stanford.edu.
⁵ Molecular Imaging Program at Stanford (MIPS), Canary Center for Cancer Early Detection at Stanford, Stanford University School of Medicine, 3155 Porter Drive, Palo Alto, CA, 94304, USA. paulmur8@stanford.edu.

Abstract

Triple-negative breast cancer (TNBC) is a highly heterogeneous breast cancer subtype with poor prognosis. Although anatomical imaging figures prominently for breast lesion screening, TNBC is often misdiagnosed, thus hindering early medical care. Ultrasound (US) molecular imaging using nanobubbles (NBs) capable of targeting tumor cells holds great promise for improved diagnosis and therapy. However, the lack of conventional biomarkers in TNBC impairs the development of current targeted agents. Here, we exploited the homotypic recognition of cancer cells to synthesize the first NBs based on TNBC cancer cell membrane (i.e., NB_CCM) as a targeted diagnostic agent. We developed a microfluidic technology to synthesize NB_CCM based on the self-assembly property of cell membranes in aqueous solutions. In vitro, optimal NB_CCM had a hydrodynamic diameter of 683 ± 162 nm, showed long-lasting US contrast enhancements and homotypic affinity. In vivo, we demonstrated that NB_CCM showed increased extravasation and retention in a TNBC mouse model compared to non-targeted NBs by US molecular imaging. Peak intensities and areas under the curves from time-intensity plots showed a significantly enhanced signal from NB_CCM compared to non-targeted NBs (2.1-fold, P = 0.004, and, 3.6-fold, P = 0.0009, respectively). Immunofluorescence analysis further validated the presence of NB_CCM in the tumor microenvironment. Circumventing the challenge for universal cancer biomarker identification, our approach could enable TNBC targeting regardless of tumor tissue heterogeneity, thus improving diagnosis and potentially gene/drug targeted delivery. Ultimately, our approach could be used to image many cancer types using biomimetic NBs prepared from their respective cancer cell membranes.

Keywords: Cancer cell membrane; Cancer early detection; Homotypic targeting; Molecular imaging; Nanobubble; Triple negative breast cancer; Ultrasound (US).

MeSH terms

Animals
Biomimetics
Cell Line, Tumor
Humans
Mice
Mice, Nude
Molecular Imaging / methods
Triple Negative Breast Neoplasms* / drug therapy
Tumor Microenvironment